Stockwinners Market Radar for February 22, 2024 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

21:03 EST JPMorgan CEO Dimon sells $150.2M in common stock - In a regulatory filing, JPMorgan disclosed that its CEO Jamie Dimon sold 821.8K shares of common stock on February 22nd in a total transaction size of $150.2M

20:04 EST Cathie Wood's ARK Investment bought 2.46M shares of Ginkgo Bioworks today

19:50 EST Lytus Technologies Holdings Ptv Ltd trading halted, news pending

19:50 EST Trinity Biotech trading halted, news pending

18:46 EST Wingstop CEO: We had a record year in 2023 - In an interview on CNBC's Mad Money, Michael Skipworth said Wingstop grew primarily by transaction growth in 2023. It ended the year with a record of pipeline commitments. "We believe we are operating in a category of one," he added. 67% of the company's sales came through digital channels in 2023, and he's looking for that to grow to 100% over time. The international business is poised for growth and he's hoping to triple it. "There's a ton of runway for us and our advertising strategy is working," he noted.

18:36 EST Tetra Tech CFO Burdick sells 7,515 common shares - In a regulatory filing, Tetra Tech CFO Steven Burdick disclosed the sale of 7,515 common shares of the company on February 22 at a price of $175.67 per share.

18:21 EST Array Technologies, Alupco announce strategic partnership - Array Technologies announced a new strategic partnership with Aluminum Products Company, an aluminum extrusion company in the Middle East and North Africa, to support the growing market for renewable energy projects in the region. Headquartered in Albuquerque, New Mexico, Array has been at the forefront of driving clean energy solutions both domestically and globally. The new partnership will bring leading solar technology to the fast-growing renewable energy market in the Middle East. "Our alliance with ALUPCO(R) and expansion into the Middle East underscores our dedication to the global clean energy market. Our partners around the world share our commitment, and consistently rely on us for our differentiators - engineered simplicity, relentless reliability and a track record built on decades of experience, performance, and trust. We're eager to bring this partnership to life with ALUPCO(R) and leverage the strengths and dedication of both organizations to transform the energy landscape," states Array CEO, Kevin G. Hostetler.

18:02 EST Banco Latinoamericano announces $50M share repurchase plan - Banco Latinoamericano announced that its Board of Directors has authorized a repurchase program of up to $50M of the Bank's common stock over time.

17:38 EST Fluence Energy responds to "misleading" short seller report - Fluence Energy issued a statement in response to a report published by a short-seller. The company believes that the report is an attempt by a self-interested short-seller to profit at the expense of Fluence's shareholders by manipulating Fluence's stock price. Highlights of the statement include: "The company believes it is important to set the record straight regarding three blatant misrepresentations:...The short-seller's report references pending litigation between Fluence and Siemens Energy...this is a small, ordinary course commercial dispute arising from a single project. Fluence brought the action to collect approximately $2M in unpaid amounts due, and Siemens Energy responded with counterclaims of approximately $9M...the case is progressing in the ordinary course. Siemens AG and its German retirement fund are investors in Fluence. Siemens AG has a minority ownership interest in Siemens Energy - it is not the same company and there is no legal case between Siemens AG and Fluence. We believe the litigation with Siemens Energy has no effect on our strong relationship with Siemens AG. The short-seller's report wrongly implies AES is moving away from Fluence as a supplier. In fact, Fluence continues to be AES' preferred Battery Energy Storage Systems technology provider..."

17:32 EST Sleep Number sees first half net sales down high single digits - Sees net sales down low single digits in second half of the year.

17:19 EST Western Copper appoints Sandeep Singh CEO - Western Copper and Gold Corporation (WRN)announces the appointment of Mr. Sandeep Singh as Chief Executive Officer of the Company, effective immediately. Mr. Singh will work closely with Dr. Paul West-Sells, who will continue in the role of President in connection with the succession process. Further, Mr. Kenneth Williamson has retired from his role as Director and Interim Chairman. Current board member, Dr. Bill Williams, has taken on the role of Interim Chairman as the Company searches for a replacement. As a highly respected mining professional with 20 years of sector expertise, Mr. Singh adds meaningful capital markets and strategic expertise to the Company. He was previously the President and CEO of Osisko Gold Royalties (OR), where he led the successful turnaround of the company.

17:11 EST SunCoke Energy CEO Michael Rippey to retire, Katherine Gates to succeed - SunCoke Energy announced that Michael Rippey intends to retire as CEO and as a member of the company's Board of Directors on May 15. The Board has unanimously appointed Katherine Gates to succeed Rippey as CEO effective May 15. Gates will retain her current position as President, serving as both President and CEO upon her promotion, and she will continue to serve as a member of the Board. Upon his retirement, it is anticipated that Rippey will serve as an advisor to the company, pursuant to an advisory agreement.

17:06 EST Tucows announces $40M stock buyback program - Tucows announced that its Board of Directors has approved a stock buyback program to repurchase, from time to time if and as appropriate, up to $40 million of its common stock in the open market. The new $40 million buyback program will commence February 23, 2024 and will terminate on or before February 22, 2025. Purchases for the new buyback program will be made exclusively through the facilities of the Nasdaq Capital Market. The previously announced $40 million buyback program, which commenced February 10, 2023, has been terminated.

17:02 EST Oceaneering sees Q1 EBITDA $50M-$60M - The decrease from the fourth quarter of 2023 is primarily due to the timing of vessel charters and two vessels undergoing planned, regulatory dry docks during the first quarter, leading to fewer available vessel days in the first quarter for OPG.

16:58 EST MercadoLibre falls 7% to $1,684 after Q4 results

16:53 EST Meritage Homes authorizes share repurchase plan of $15M per quarter - Meritage has instituted a formal share repurchase plan with a minimum buyback commitment of $15M in each quarter of this fiscal year. In January and February 2024, the company has already repurchased its $15M Q1 amount and an additional $41M of shares, leaving a minimum of $45M to be repurchased the rest of the year. Meritage intends to review and renew its share repurchase commitment annually.

16:46 EST Red River Bancshares raises quarterly dividend to 9c from 8c per share - Red River Bancshares announced that on February 22, its board of directors declared a cash dividend of 9c per share of common stock, representing a 1c, or 12.5%, increase from the quarterly cash dividend of 8c per share declared on October 26, 2023. The cash dividend is payable on March 21 to shareholders of record as of the close of business on March 11.

16:41 EST MSA Safety appoints COO Steve Blanco as CEO effective May 10th - MSA Safety has elected Steve Blanco as CEO, effective May 10, which follows the company's annual meeting of shareholders. The Board has also elected Blanco as a director of the company, effective immediately. Blanco currently serves as MSA's President and COO. His election is part of a planned management succession and coincides with a decision by MSA Chairman and CEO Nish Vartanian to inform the Board of Directors that he intends to retire as CEO in May of this year. Blanco joined MSA in 2012 as VP of Global Operational Excellence. In 2017, he was named President of MSA Americas, responsible for the company's business in the U.S., Canada, and Latin America. Vartanian intends to continue his service on the MSA Board. Prior to joining MSA, Blanco worked for Eaton Corporation, a global and diversified power management company. Prior to that, he worked for Ford Motor Company and Visteon, serving in a variety of engineering, plant management and operations roles.

16:37 EST Fannie Mae appoints Peter Akwaboah COO - Fannie Mae announced Peter Akwaboah has been appointed executive VP and COO, effective May 20. Akwaboah has nearly three decades of experience from across the financial services industry and will be responsible for Fannie Mae's Chief Information Office, Enterprise Operations, Business Resiliency, and Enterprise Workplace and Security functions. In this role, Akwaboah will be a member of Fannie Mae's Management Committee and report to CEO Priscilla Almodovar.

16:34 EST NOV Inc. opens regional headquarters in Dammam, Saudi Arabia - NOV Inc. announced the establishment of its regional headquarters in Dammam, Saudi Arabia. The regional headquarters further emphasizes NOV's commitment to the region and to delivering exceptional products, services, and solutions to its valued customers in this vital market. Situated at the prestigious Dammam Asharqia Chamber Tower, the facility will serve as a pivotal hub for NOV's operations in the Middle East and will house a talented team of executive leadership, engineers, and professionals' functions. By consolidating these crucial functions in Dammam, NOV aims to enhance operational efficiency, foster closer collaboration with regional stakeholders, and further strengthen its market position.

16:34 EST Booking Holdings down 5% after Q4 report - Shares of Booking Holdings are down $191.99, or 5%, to $3,710.00 in after-hours trading following the company's Q4 report.

16:31 EST Alarm.com sees Q1 SaaS/license revenue $148.6M-$148.8M

16:26 EST Applied Optoelectronics files patent infringement lawsuit against CIG - Applied Optoelectronics announced that it has filed a complaint for patent infringement against Cambridge Industries USA, or CIG, in the U.S. District Court for the Northern District of California, Case No.: 5:24-cv-01010. The complaint, filed February 20, alleges that at least the CIG 100G QSFP28 CWDM4 Module Version 1, the CIG 100G QSFP28 CWDM4 Module Version 2, the CIG 100G LR4 Module, the CIG 400G QSFP-DD DR4 Module, the CIG 400G QSFP-DD FR4 Module, and the CIG 100G QSFP28 PSM4 optical transceiver module infringe one or more of the eight asserted of Applied Optoelectronic optical transceiver patents. "This lawsuit against CIG is a necessary step to protect AOI's intellectual property that has been obtained through research and development, innovation, and investment. AOI will vigorously enforce its IP rights against alleged infringers," said Dr. Thompson Lin, Applied Optoelectronics, CEO.

16:25 EST BankUnited raises quarterly dividend 7.4% to 29c per share - BankUnited announced that its Board of Directors has declared a quarterly cash dividend of $0.29 per common share, reflecting a 7.4% increase from the previous quarterly cash dividend of $0.27 per common share. The dividend will be payable on April 30, 2024 to stockholders of record at the close of business on April 12, 2024.

16:23 EST American Homes 4 Rent CEO David Singelyn to retire, Bryan Smith to succeed - AMH announced that David Singelyn, who has served as CEO since the company's inception, has announced his intent to retire effective December 31, 2024. The company's Board of Trustees has named Bryan Smith, the company's COO, as the next CEO effective January 1, 2025. Subsequently, Singelyn will serve as an advisor through June 2025. In addition, the Board has promoted Christopher Lau, the company's CFO, to the elevated role of Senior Executive Vice President.

16:22 EST EOG Resources sees FY24 CapEx $6B-$6.4B

16:21 EST AFC Gamma to spin off CRE portfolio into independent, publicly traded company - AFC Gamma announced that its board has unanimously approved a plan to spin-off its commercial real estate, or CRE, portfolio into an independent, publicly traded company that intends to elect REIT status, Sunrise Realty Trust. The spin-off will result in two pure-play debt capital providers - one focused solely on the cannabis industry and a second on CRE in the southern United States. AFC Gamma believes that the separation will allow both companies to focus on their respective portfolios, articulate their own clear investment thesis, and have the flexibility to tailor their business strategies to best capture market opportunities within their specialization. The separation is expected to be completed in mid-2024.

16:18 EST Brightcove announces Rob Noreck to step down as CFO by May 31 - Brightcove is announcing a CFO transition plan. Rob Noreck will be stepping down as the company's CFO on May 31, 2024, or earlier if his successor is named prior to that date. Noreck will serve as a consultant to the company through September 30, 2024 to ensure a smooth transition process. "We have initiated an executive search process and expect to name a successor as quickly as possible."

16:16 EST Essex Property Trust raises quarterly dividend 6.1% to $2.45 per share - Essex Property Trust announced that its Board of Directors has approved a 6.1% increase to its annual cash dividend. This represents the Company's 30th consecutive annual dividend increase. The Board of Directors has declared a first quarter dividend of $2.45 per share, payable on April 12, 2024 to shareholders of record as of March 29, 2024. On an annualized basis, the dividend represents a distribution of $9.80 per common share.

16:13 EST Ligand partner Eisai receives Japan approval for Fycompa injection - Ligand Pharmaceuticals (LGND) "announced that its partner Eisai Co. (ESAIY) obtained marketing authorization approval in January 2024 from the Japanese Ministry of Health, Labour and Welfare for the injection formulation of its in-house discovered antiepileptic drug Fycompa, or perampanel, in Japan as an alternative therapy when oral administration is temporarily not possible. Fycompa is formulated with Captisol(R), a Ligand technology. Fycompa is a first-in-class AED discovered at Eisai's Tsukuba Research Laboratories. The agent is a highly selective, noncompetitive AMPA receptor antagonist that is postulated to reduce neuronal hyper-excitation associated with seizures by targeting glutamate activity at AMPA receptors on postsynaptic membranes. Two oral formulations of Fycompa are available in Japan: a tablet and a fine granule formulation. "

16:09 EST Ocugen announces dosing completion in Phase 1/2 GARDian clinical trial - Ocugen announced that dosing is complete in the first cohort of its Phase 1/2 GARDian clinical trial for OCU410ST (AAV5-hRORA)-a modifier gene therapy candidate being developed for Stargardt disease. Stargardt disease is an orphan blindness disease that affects approximately 35,000 people in the United States alone. "This is an important clinical milestone for our first-in-class, potential one-time therapy for the treatment of Stargardt disease," said Dr. Arun Upadhyay, Chief Scientific Officer and Head of R&D at Ocugen. "Although Stargardt is one of the most common inherited retinal diseases, there remains no treatment option to address this condition. OCU410ST provides hope to these patients who may eventually lose their vision."

16:08 EST Celcuity announces first patient dosed in Phase 1b/2 CELC-G-201 clinical trial - Celcuity announced that the first patient has been dosed in its Phase 1b/2 study evaluating gedatolisib in combination with Nubeqa, an approved androgen receptor inhibitor, for the treatment of patients with metastatic castration resistant prostate cancer. Gedatolisib, the company's lead therapeutic candidate, is a potent, reversible dual inhibitor that selectively targets all Class 1 PI3K isoforms and mTORC1/2. "We are excited to begin enrolling patients in our 201 trial and advancing towards our ultimate goal of providing a transformative therapeutic option for patients with prostate cancer," said Igor Gorbatchevsky, M.D. Chief Medical Officer of Celcuity. "A significant unmet need remains for patients with metastatic castration resistant prostate cancer who have become resistant to a next generation androgen receptor inhibitor." In August 2023, Celcuity announced that it had entered into a clinical trial collaboration and supply agreement with Bayer AG to provide Nubeqa to Celcuity at no cost for the Phase 1b/2 trial.

16:04 EST Booking Holdings CEO 'confident in long-term growth of leisure travel' - Glenn Fogel, Chief Executive Officer of Booking Holdings, stated: "We are pleased to report a strong close to 2023 with fourth quarter room nights growing 9% year-over-year or 11% when excluding business associated with Israel, which was significantly impacted by the war. For the full year, we reached a significant milestone with over 1 billion room nights booked on our platforms, and we achieved record levels of gross bookings, revenue, and operating income. We are confident in the long-term growth of leisure travel and in the opportunities ahead for our company as we continue our work to deliver a better offering and experience for our supply partners and our travelers."

16:03 EST Booking Holdings initiates quarterly dividend of $8.75 per share - Booking Holdings' board of directors declared a quarterly cash dividend of $8.75 per share, payable on March 28 to stockholders of record as of the close of business on March 8. "We expect to pay a cash dividend on a quarterly basis going forward, subject to our Board's consideration of, among other things, market conditions and our financial performance and cash flows," the company stated.

15:16 EST AT&T says wireless service restored to all affected customers - AT&T stated in a network update: "We have restored wireless service to all our affected customers. We sincerely apologize to them. Keeping our customers connected remains our top priority, and we are taking steps to ensure our customers do not experience this again in the future." Reference Link

15:07 EST FaZe Holdings announces stockholder approval for merger with GameSquare - FaZe Holdings (FAZE) announced that its stockholders have voted to approve the proposed merger with GameSquare (GAME). GameSquare's stockholder vote will be held on February 27, at 10:00 a.m. ET. FaZe Clan and GameSquare anticipate the transaction closing shortly thereafter, subject to the satisfaction of customary closing conditions.

15:03 EST Alerus Financial names Forrest Wilson chief retirement services officer - Alerus Financial Corporation announced that Forrest Wilson will join Alerus as Executive Vice President and Chief Retirement Services Officer, effective February 26, 2024. A well-rounded retirement industry veteran, Mr. Wilson brings over 25 years of experience on both the platform/recordkeeping and investment sides of the retirement business. He has extensive knowledge in sales and distribution growth, product oversight and strategy, acquisitions, digital engagement, implementation, and service delivery, and has a proven track record in leading teams of all sizes to reach and exceed significant goals. Before joining Alerus, he spent six years at Ameritas Mutual Holding Company and served most recently as Senior Vice President of Retirement Plans Sales and Distribution, where he was accountable for all aspects of the business strategy, including several successful acquisitions, while consistently delivering strong results. Prior to that, he served in various management and sales leadership roles with firms including Allianz Global Investors, Aspire Financial Services, Empower, and Voya.

14:34 EST Intuitive Machines updates anticipated landing time for IM-1 mission - Intuitive Machines tweeted: "Flight controllers chose to exercise an additional orbit before starting the IM-1 Mission landing sequence. The new anticipated landing time is 1724 CST. We expect the landing stream to start on the IM-1 web page and NASA TV at 1600 CST. The content on both streams is identical." Reference Link

14:20 EST Reddit expands model training partnership with Google - Reddit said it has expanded its partnership with Google to make it easier to discover and access the communities and conversations people are looking for on Reddit. "With this partnership, and via our Data API, we're ushering in new ways for Reddit content to be displayed across Google products by providing programmatic access to new, constantly evolving, and dynamic public posts, comments, etc., on Reddit," Reddit said. "This enhanced collaboration provides Google with an efficient and structured way to access the vast corpus of existing content on Reddit and enables Google to use the Reddit Data API to improve its products and services - including supporting new ways to display Reddit content and providing more efficient ways to train models. Our work with Google will make it easier for people to find, discover, and engage in content and communities on Reddit that are most relevant to them." Reference Link

12:41 EST Sony testing PlayStation VR2 support for PC - Sony said that it is currently testing the ability for PlayStation VR2 players to access additional games on PC to offer even more game variety in addition to the PS VR2 titles available through PS5. "We hope to make this support available in 2024, so stay tuned for more updates," the company said. Reference Link

12:13 EST Spree Acquisition Corp 1 Ltd trading halted, news pending

12:02 EST United Airlines opens new building at Flight Training Center in Denver - United opened a new, 150,000-square-foot building at its Flight Training Center in Denver. Already the largest facility of its kind in the world, the additional building gives the airline the capability to add 12 more advanced full-motion flight simulators to the facility, six of which have already been delivered. So far in 2024, the airline has hired more than 300 pilots after hiring more than 2,300 pilots last year. The new building at the campus adds even more training capacity for United's 16,000 pilots. United's Flight Training Center now has eight total buildings, more than 700,000 square feet of training space, and 46 state-of-the-art full-motion flight simulators.

12:00 EST Arcus Biosciences rises 17.7% - Arcus Biosciences is up 17.7%, or $2.90 to $19.31.

12:00 EST Bridge Investment falls -15.3% - Bridge Investment is down -15.3%, or -$1.33 to $7.39.

12:00 EST iShares Core S&P Mid-Cap ETF falls -79.8% - iShares Core S&P Mid-Cap ETF is down -79.8%, or -$223.87 to $56.81.

11:23 EST Williams Rowland Acquisition to redeem public shares and liquidate - Williams Rowland Acquisition Corp. announced that it will liquidate and dissolve the company in accordance with the provisions of the company's amended and restated certificate of incorporation, as amended. Accordingly, the company will redeem all outstanding shares of its common stock sold in its initial public offering that remain outstanding, effective as of March 8. The company had until March 29 to complete an initial business combination provided that for each one-month extension from July 29, 2023 through March 29, the company deposited into the trust account established in connection with its initial public offering the lesser of $50,000 or 2c per shares sold in the IPO that remained outstanding. The board has determined that it will not be able to complete an initial business combination by March 29. The last day that the company's securities will trade on the NYSE American will be February 29. As of March 8, the public shares will be deemed cancelled and will represent only the right to receive the redemption amount.

11:02 EST Newmont completes COO transition - Newmont Corporation announced the completion of its COO transition following a five-month handover period. Beginning next week, Rob Atkinson will transition all of his remaining responsibilities to Newmont's new COO, Natascha Viljoen. He will then officially step down from the Newmont Executive Leadership Team, effective May 2, 2024.

10:38 EST Williams Rowland Acquisition Corp trading halted, news pending

10:32 EST Verizon says network 'remains fully operational' - Verizon issued the following statement: "Verizon's network remains fully operational. Some customers may have experienced issues this morning when calling or texting those served by another carrier. Our network continues to function normally."

10:15 EST Teamsters authorize strike at Republic Services in Indiana - Members of Teamsters Local 364 in Culver, Indiana, have unanimously authorized a strike at Republic Services, the union state in a statement. "The strike authorization is a direct result of the company's refusal to bargain in good faith and its blatant disregard for federal labor laws," the union said.

10:06 EST Kuke Music to enter classical music car connectivity market in Q2 - Kuke Music plans to officially enter the classical music car connectivity market in the second quarter of 2024. This strategic move is accompanied by the launch of a new application designed exclusively for individual end-users, aimed at providing classical music enthusiasts with a more convenient and high-quality music experience. The all-new car connectivity application will be integrated into the onboard systems of various vehicle brands, offering unparalleled classical music experiences for drivers and passengers during their journeys. This user-friendly application, tailored for end-users, is known for its intuitive interface and simple operation, with the goal of delivering a smooth and seamless music playback experience. Users will be able to access and play their favorite classical music pieces effortlessly through various interactive methods, including voice control and touchscreen.

10:01 EST L Catterton Asia Acquisition Corp trading resumes

10:00 EST VeriSign Inc rises 15.4% - VeriSign Inc is up 15.4%, or $10.99 to $82.50.

10:00 EST Bridge Investment falls -13.2% - Bridge Investment is down -13.2%, or -$1.15 to $7.57.

10:00 EST iShares Core S&P Mid-Cap ETF falls -79.8% - iShares Core S&P Mid-Cap ETF is down -79.8%, or -$223.94 to $56.74.

09:55 EST RumbleON names Brandy Treadway as Chief Legal Officer - RumbleOn (RMBL) announced the appointment of Brandy Treadway as the company's Senior Vice President and Chief Legal Officer. Treadway brings over two decades of legal expertise, including executive positions at J.C. Penney Company (JCP) and as a partner at Martin Powers & Counsel, PLLC. Treadway will lead RumbleOn's legal and human resources functions.

09:47 EST Mativ rises 12.2% - Mativ is up 12.2%, or $1.43 to $13.19.

09:47 EST Olo rises 15.1% - Olo is up 15.1%, or 87c to $6.65.

09:47 EST Fiverr falls -10.7% - Fiverr is down -10.7%, or -$2.78 to $23.11.

09:47 EST iShares Core S&P Mid-Cap ETF falls -79.9% - iShares Core S&P Mid-Cap ETF is down -79.9%, or -$224.14 to $56.54.

09:45 EST California airport to implement 22 K1 Blue Light Emergency Phones - Knightscope announces that one of the busiest international airports for travelers and cargo in the United States is upgrading its emergency communications with 22 new K1 Blue Light Emergency Phones. The E-Phones will be installed throughout a prime parking lot at the airport.

09:40 EST AT&T says some customers having wireless service interruptions - AT&T spokesman Jim Greer said in a statement: "Some of our customers are experiencing wireless service interruptions this morning. We are working urgently to restore service to them. We encourage the use of Wi-Fi calling until service is restored."

09:35 EST Bel Fuse trading resumes

09:35 EST TC Biopharm announces MHRA acceptance of amendment for ACHIEVE UK trial - TC BioPharm announced that the Medical and Healthcare Products Regulatory Agency, or MHRA, has officially accepted its proposed amendment to the company's clinical trial authorization, or CTA. The amendment allows for an increase in dosing size of TCB008. Additionally the amendment allows for patients to be treated as "out patients", easing the burden on patients and lessening the burden on clinical sites as patients will not need to be monitored overnight after the first five patients are dosed. The ACHIEVE trial is a Phase 2b trial in Acute Myeloid Leukemia testing efficacy for TCBPs lead product TCB-008, or Omnimmune. Bryan Kobel, Chief Executive Officer of TC BioPharm stated, "Management is pleased to receive amendment clearance from the MHRA, this is yet another example of the team executing on plans we have laid out for the investment community. The changes to the protocol will substantially impact both the timing of data in the ACHIEVE trial as well as impacting the proposed FDA trial. Shifting to an out patient procedure means patients in the trial are not forced to spend a night in the hospital, increasing their quality of life in a difficult time, and also allows hospitals to not need to hold a bed for a patient in a time when beds are scarce in the NHS. We believe, after feedback from the clinical sites, that this was a material rate limiting concern in enrolment and are happy we can now provide them relief. Increasing the dose size, in accordance and discussion with our investigators, can increase the positive impact in patients with no safety concerns, furthering our stance that TCB-008 should be used in a myriad of settings at high doses. This step also aligns the dosing levels with the IND, where our second cohort would be receiving this dose, and gives us a window to approach the FDA with data at this level to potentially go immediately to dose level two in our US Phase 1b in relapse/refractory AML."

09:33 EST Trupanion enrolls one millionth subscription pet - Trupaniont has enrolled its one millionth subscription pet across its portfolio of subscription brands in North America and Continental Europe. The one-millionth subscriber, Boz, an Australian Cattle Dog puppy from Connecticut, was enrolled in Trupanion's medical insurance coverage. Boz is the third pet in his household to be protected by Trupanion, joined by his fur sister Maggie, who holds the distinction of being Trupanion's one-million and one subscription pet.

09:30 EST Mativ Holdings trading halted, volatility trading pause

09:23 EST Tennant and Brain in technology pact to accelerate robotic floor cleaning - Tennant Company and Brain Corp, a leading autonomous technology company creating transformative solutions in robotics and artificial intelligence AI , jointly announce an exclusive technology agreement to accelerate the development and adoption of the next generation of robots in the floor-cleaning industry. This landmark agreement builds on the historically successful partnership between the two companies and seeks to accelerate innovation. Tennant and Brain Corp bring complementary strengths to the relationship that create an exceptional customer support ecosystem. Tennant has a 150-plus year history of building industry-leading cleaning equipment and has expansive direct sales and service coverage. Brain Corp offers industry-leading and AI-enabled AMR cleaning technology, with more than 6,500 Tennant cleaning robots in the field powered by Brain. We expect Tennant's purpose-built robotic equipment driven by Brain Corp's next-generation and AI-enabled autonomous navigation technology will improve the customer return on investment and enable more customers to invest in robotic cleaning.

09:19 EST Waldencast announces formation of Creative Council - Waldencast announced the formation of a new Creative Council. The interdisciplinary team of industry disruptors will come together to help Waldencast stay ahead of the curve by ideating on long-term macro and micro-trends in the beauty and wellness industry, and to ensure the Company evolves to meet customer needs now and in the future. The Creative Council will be led by Mazdack Rassi, Co-Founder and Chief Brand Officer at Milk Makeup and newly-appointed Global Brand Director at Waldencast. Each member of the Creative Council has founded or built businesses that positively impact their respective industries across beauty, retail, design, branding, and more. In addition to Mr. Rassi, the members include: Mona Kattan, Founder of Kayali Fragrances, and Co-Founder and Global President of Huda Beauty; Geoff Cook, Partner at Base Design; Jyothi Rao, Board Director, Strategic Advisor & Mentor; Piers North, Creative Director; Brooke Wall, Founder and Chairperson of The Wall Group; Roger Schmid, Fragrance Expert Executive,

09:17 EST U.S. Bancorp C&I, credit card loans performing well, says CFO - Comments taken from the Bank of America 2024 Financial Service Conference.

09:13 EST Agile Therapeutics announces exercise of warrants for $4.8M gross proceeds - Agile Therapeutics announced the entry into a definitive agreement for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 3,892,572 shares of common stock of the Company originally issued in July 2022 and May 2023, having an exercise price of $3.69 per share, at a reduced exercise price of $1.25 per share. The shares of common stock issuable upon exercise of the warrants are registered pursuant to effective registration statements on Form S-1 and Form S-1MEF. The gross proceeds to the Company from the exercise of the warrants are expected to be approximately $4.8 million, prior to deducting placement agent fees and estimated offering expenses. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering. In consideration for the immediate exercise of the warrants for cash, the Company will issue new unregistered warrants to purchase shares of common stock. The new warrants will be exercisable for an aggregate of up to 7,785,144 shares of common stock, at an exercise price of $1.00 per share and will be immediately exercisable upon issuance. 3,992,572 of the new warrants will have a term of five years from the issuance date and 3,792,572 of the new warrants will have a term of eighteen months from the issuance date. The offering is expected to close on or about February 26, 2024, subject to satisfaction of customary closing conditions. The Company intends to use the net proceeds from the offering for working capital and general corporate purposes.

09:12 EST Edible Garden announces new grant funding from Michigan Department of LEO-WD - Edible Garden announced that the Company has received funding from the Going PRO Talent Fund, awarded by the Michigan Department of Labor and Economic Opportunity - Workforce Development, LEO-WD, facilitated through Michigan Works! This funding is aimed at reimbursing employers in Western Michigan for costs incurred in the training, development, and retention of both existing and new employees. Jim Kras, Chief Executive Officer of Edible Garden, commented, "The grant will reimburse the Company for training expenses for our staff at the Edible Garden Heartland facility in Grand Rapids, Michigan, in crucial areas such as supply chain management, transportation, and logistics. Additionally, it will cover on-the-job training costs for new hires at the facility, expected to fill positions like Food Safety Officer, General Manager, and Grower."

09:11 EST Fat Brands opens Fatburger location in Celebration, Florida - FAT Brands announces the opening of the latest Fatburger location in Celebration, FL. The opening marks the iconic burger brand's debut in the Orlando area and is the second of 14 locations under development in Orlando and western Florida.

09:09 EST SEALSQ Corp. provides progress update on Post-Quantum Semiconductors program - SEALSQ provides a progress update on its Post-Quantum Semiconductors program. The company said, "In the rapidly evolving landscape of quantum computing, SEALSQ is at the forefront of innovation with its introduction of post-quantum semiconductors. These cutting-edge chips are designed to significantly enhance security, identification and data processing capabilities, ensuring a leap forward in Artificial Intelligence performance, security, and efficiency. SEALSQ's portfolio, encompassing semiconductors, secure elements, roots of trust, cryptographic keys, and hardware security modules, demonstrates an unwavering commitment to technological advancement and security. These innovations are essential in an era where the AI divide is increasingly pronounced, and the need for robust, quantum-resistant technologies has never been more critical." Key Innovations of SEALSQ Post-Quantum Chips: Quantum Speedup: By leveraging quantum superposition, SEALSQ chips offer unprecedented data processing capabilities. This advancement is set to revolutionize AI training times and inferencing speeds. Quantum Annealing & Optimization: These chips utilize quantum annealing to expedite the discovery of optimized solutions, a game-changer for machine learning applications. Quantum Machine Learning: At the core of SEALSQ's technology is pioneering quantum machine learning research, promising to enhance AI performance, speed, and accuracy. Post-Quantum Cryptography: In response to emerging security challenges, SEALSQ chips are built with post-quantum cryptographic methods, offering protection against quantum computing threats. Quantum Networking & Communication: The chips incorporate quantum communication methods, including quantum key distribution, to ensure ultra-secure data transmission. Quantum-enhanced Sensor: Featuring advanced quantum-based sensors, SEALSQ chips provide the semiconductor industry with superior precision in testing and quality control.

09:07 EST Winnebago, Xos announce partnership, development of electric chassis - Xos (XOS) and Winnebago, the flagship brand of outdoor lifestyle product manufacturer Winnebago Industries (WGO), announce a partnership and development of a fully electric chassis for Winnebago's Specialty Vehicles division. This chassis utilizes proven Xos battery and electronics technology and is customized for Winnebago's unique commercial applications. "We are thrilled to partner with Winnebago to move the industry forward," said Dakota Semler, CEO and Co-Founder of Xos, Inc. "This is a testament to the quality and reliability of our products, and to the customer-centered design approach of Winnebago's Specialty Vehicle team. This partnership combines the strengths of both companies and positively impacts the communities these vehicles serve."

09:04 EST STMicroelectronics expands into 3D depth sensing with time-of-flight sensors - STMicroelectronics announced an all-in-one, direct Time-of-Flight 3D LiDAR module with market-leading 2.3k resolution, and revealed an early design win for the world's smallest 500k-pixel indirect Time-of-Flight sensor. The VL53L9 is a new direct ToF 3D LiDAR device with a resolution of up to 2.3k zones. Integrating a dual scan flood illumination, unique in the market, the LiDAR can detect small objects and edges and captures both 2D infrared images and 3D depth map information. It comes as a ready-to-use low power module with its on-chip dToF processing, requiring no extra external components or calibration. Additionally, the device delivers state-of-the-art ranging performance from 5cm to 10 meters. ST is also announcing news of its VD55H1 ToF sensor, including the start of volume production and an early design win with Lanxin Technology, a China-based company focusing on mobile-robot deep-vision systems. MRDVS, a subsidiary company, has chosen the VD55H1 to add high-accuracy depth-sensing to its 3D cameras. The high-performance, ultra-compact cameras with ST's sensor inside combine the power of 3D vision and edge AI, delivering intelligent obstacle avoidance and high-precision docking in mobile robots.

09:03 EST Senmiao Technology signs cooperation agreement for AI-driven application - Senmiao Technology's operating subsidiary Sichuan Senmiao Zecheng has signed a strategic cooperation agreement with Chengdu Daren Duoduo, a Multi-Channel Network company focused on providing group purchasing services for local lifestyle merchants and the training and incubation of store-exploring influencers. Zecheng and Daren Duoduo will jointly develop an AI-driven application called "Thinking Cell," designed to provide customized operation support and services to local lifestyle merchants in their promotional and sales efforts, and to online ride-hailing drivers who Senmiao serves on its platform. It is expected that Thinking Cell will support Senmiao's SMS promotional campaigns and enable Senmiao's drivers to provide customized services for their customers. Zecheng and Daren Duoduo will also explore the possibility of expanding Thinking Cell into additional application scenarios.

08:59 EST U.S. Bancorp sees FY24 NII $16.6B+, noninterest income up mid single digits - Sees noninterest expense roughly $17B.

08:57 EST Nikola delivered 35 hydrogen fuel cell electric trucks in Q4 - Delivered the first production hydrogen fuel cell electric truck available in North America. Delivered 35 hydrogen fuel cell electric trucks in Q4 ending the period with no finished goods inventory. From October 2023 through January 31, 2024, 225 additional voucher requests have been submitted in Calif. for hydrogen fuel cell electric trucks, all for Nikola. Remain on track to get the first battery-electric trucks back into end user hands by the end of Q1. Opened first HYLA modular refueling station in Ontario, Calif. and announced partnership with FirstElement Fuel in Oakland, Calif. providing fleets with fueling solutions in Northern and Southern Calif. During Q4 raised $230.3M, ending the year with $464.7M of unrestricted cash, highest unrestricted cash balance since Q4 2021.

08:50 EST Tenon Medical announces issuance of notice of allowance of patent application - Tenon Medical announced that on February 15, 2024, the United States Patent and Trademark Office issued a Notice of Allowance for U.S. Patent Application Serial Number 18/107,536 for Tenon's Catamaran SI Joint implant for stabilizing a dysfunctional sacroiliac joint. A U.S. patent based on U.S. Patent Application Serial Number 18/107,536 should thus issue within the next ninety days. The U.S. Patent, when issued, will further enhance the Company's growing patent portfolio for its Catamaran SI Joint implant system, which now comprises eight issued U.S. and foreign patents, and twenty-three pending U.S. and foreign patent applications.

08:48 EST Gracell announces completion of acquisition - Gracell Biotechnologies (GRCL) announced the completion of its previously announced agreement to be acquired by AstraZeneca (AZN), in accordance with the terms and conditions of the Agreement and Plan of Merger, dated as of December 23, 2023, by and among the Company, AstraZeneca Treasury Limited, a private limited company incorporated under the laws of England and Wales, and Grey Wolf Merger Sub, an exempted company with limited liability incorporated under the laws of the Cayman Islands and a wholly owned subsidiary of Parent. The acquisition was structured as a merger of Merger Sub with and into the Company with the Company surviving the merger as a wholly owned subsidiary of Parent. As a result of the Merger, the Company ceased to be a publicly traded company and became a wholly owned subsidiary of Parent.

08:47 EST EC grants 'orphan medicinal product designation' to Arcturus' ARCT-032 for CF - Arcturus Therapeutics Holdings announced that the European Commission EC, based on a positive opinion issued by the European Medicines Agency, EMA , has granted orphan medicinal product designation for the Company's product candidate ARCT-032 to treat Cystic Fibrosis CF . In November 2023, the U.S. Food and Drug Administration FDA granted orphan drug designation to ARCT-032 for CF. "We are pleased to receive orphan medicinal product designation from the EC for ARCT-032, as it represents a significant milestone for our CF program," said Joseph Payne, President & CEO of Arcturus Therapeutics. "We will continue to advance ARCT-032 as a potential new treatment option for people with CF regardless of their genetic mutations." After successful completion of the single-ascending-dose portion of the study in healthy adults, the first participant with CF in the Phase 1b study part enrolled and completed two administrations of ARCT-032. Arcturus remains on track to share interim Phase 1b data in H1 2024.

08:45 EST Verses Technologies challenges AI industry with benchmark tests - VERSES AI provides a research roadmap that outlines the key milestones and benchmarks against which to measure the progress and significance of the Company's research and development efforts, against conventional deep learning, for the benefit of industry, academia, and the public. "We laid out a roadmap... which we expect to use to demonstrate over the course of this year that VERSES' approach to AI is able to match or exceed the performance of advanced AI models on multiple industry-standard benchmarks while using materially less data and energy," said Gabriel Rene, founder and CEO of VERSES.

08:44 EST Rogers Corporation leases Monterrey, Mexico facility or advanced busbar services - Rogers Corporation announced that it has signed a lease on a factory in Monterrey, Mexico for advanced busbar manufacturing and engineering services. The first phase of the new site is slated for completion in late 2024 and continues Rogers' manufacturing footprint strategy of supporting customers in the regions where they operate. "We are excited to expand our presence in North America to better support our global customers and the growing EV/HEV and renewable energy markets in this region. Our new factory in Monterrey will enable us to better support our customers with deeper technical collaboration, and local prototyping and supply capabilities that reduce lead times and improve service levels," said Jeff Tsao, Advanced Electronic Solutions (AES) Senior Vice President and General Manager.

08:43 EST Avenue Therapeutics announces publication of preclinical data of BAER-101 - Avenue Therapeutics announced the publication of preclinical in vivo data in Drug Development Research highlighting BAER-101's full suppression of seizure activity using the Genetic Absence Epilepsy Rats from Strasbourg model of absence epilepsy. Data published showcase BAER-101's ability to selectively target GABAA alpha2 and alpha3 subtypes more than alpha1 and alpha5, potentially improving anti-convulsant and anxiolytic activity while minimizing the risk of tolerance and abuse associated with existing treatments in this drug class. The publication describes the extent of anti-seizure activity of BAER-101 in the GAERS model, a widely used and translationally relevant animal model. The study demonstrated full suppression of seizure activity with a minimal effective dose of 0.3 mg/kg. The effect of BAER-101 was fast in onset and stable throughout the duration of testing. Results from the testing showed that the number of spike-wave discharges were dose-dependently reduced by BAER-101, and no adverse safety events were observed up to a dose 300x the MED.

08:40 EST Danimer Scientific expands Rinnovo demonstration plant capacity - Danimer Scientific announced it has successfully completed the expansion of its Rochester, NY demonstration plant in order to better serve partners for the testing of Rinnovo polymers. Rinnovo is a type of polyhydroxyalkanoate synthesized using a thermocatalytic process, which the Company believes can be produced at a lower cost than PHA produced via fermentation processes. The Rinnovo product platform boasts unique properties relative to currently marketed PHA materials, including enhanced barrier properties, increased elongation and a lower melting temperature. Danimer expects the capital cost to build out future commercial capacity of Rinnovo will be significantly less than commercial plants using fermentation processes to produce other types of PHAs. When operated continuously, the expanded demonstration plant can produce 20 tonnes annually, which marks an approximate 20x scale up from the previous production capacity. Key features of the expansion project include a larger carbonylation reactor, installation of three additional fractional distillation towers, a larger polymerization reactor and a polymer drying unit. The demonstration plant also features enhanced controls and data collection that will support additional process condition testing and optimization of the commercial plant design. Stephen E. Croskrey, Chief Executive Officer of Danimer, said, "We are thrilled to have the Rinnovo demonstration plant expansion completed, allowing us to accelerate our efforts to gain offtake commitments for this

08:39 EST Nextech3D.AI expands AI tech team by doubling office space in India - Nextech3D.ai announced the expansion of its AI tech team by doubling its office space in Hyderabad, India, to accommodate its expanding team. The Company is also in negotiations for a major license of its GPT AI 3D modeling CAD to 3D and texturing technology. Nextech3D.ai will continue to supply 3D models to the largest brands and .platforms as it gears up increasing revenue and profit margins by signing licensing deals with global manufactures that have CAD files.

08:38 EST AlTi Global gets $450M investment by Allianz X and CWC, advancing M&A capacity - AlTi Global announced a strategic investment of up to $450M by Allianz X and Constellation Wealth Capital or CWC . Allianz X, an investment arm of Allianz SE will invest up to $300M through one of its affiliates. CWC, an investment advisory firm specializing in making investments in industry-leading wealth managers, will invest $150M. AlTi will use the capital principally to fund its mergers and acquisitions M&A pipeline and organic growth activities. This will expand the scale and reach of AlTi's global ultra-high-net-worth or UHNW wealth management and strategic alternatives business in existing and new markets, leveraging the industry expertise and relationships of both Allianz and CWC. The partnership with Allianz offers opportunities to provide additional solutions to service both companies' clients more holistically. Nazim Cetin, Chief Executive Officer of Allianz X, and another Allianz representative will be appointed to AlTi's Board of Directors, and CWC will have an observer seat on the Board, upon completion of their respective investments.

08:36 EST ProSomnus reports pilot study validation of next generation RPM device - ProSomnus announced of its pilot study for the Company's Next Generation Remote Patient Monitoring, RPM, device for Obstructive Sleep Apnea, OSA. Data from the pilot study demonstrated that an oximeter embedded in a precision medical device can accurately, safely, and continuously monitor SpO2. "This pilot study validation represents a step toward bringing sleep medicine into the P4 medicine era. The ProSomnus RPMO2 OSA Device enables sleep medicine to be more personalized, predictive, preventative, and participatory," commented Len Liptak, Chief Executive Officer for ProSomnus Sleep Technologies. "Although we have more work to do in terms of FDA clearances, market access and commercialization, I am very proud that team ProSomnus is in the process of bringing this potentially life changing innovation to the millions of people suffering from OSA."

08:35 EST Workhorse Group adds Riverview International Trucks as fifth California dealer - Workhorse Group announced it has added Riverview International Trucks as its latest vehicle dealer, bringing the Company's total dealer count in California to five. Through this partnership Riverview will be offering the full suite of Workhorse's commercialized product line, including the W4 CC, W750, and W56, to current and potential customers throughout the region. "This strategic partnership represents another step forward in our ongoing expansion efforts in California," said Workhorse CEO Rick Dauch. "We believe that our purpose-built trucks and Riverview's experience selling and servicing customers in the region will allow us to capitalize on attractive EV incentives offered by the state. We look forward to partnering with the Riverview team as they build out their catalogue of electric vehicles to meet growing demand in the region and statewide."

08:33 EST Intapp to acquire AI software company delphai, terms not disclosed - Intapp signed an agreement to acquire delphai, a Berlin-based AI software company specializing in applied AI for firmographic data automation, structuring, and intelligence. The transaction is subject to regular and customary closing conditions and is expected to close within the next 60 days. Delphai applies AI across public data from tens of millions of company websites, news sources, financial statements, and more, creating structured, attributable firmographic data. The company's technology streamlines firmographic data analysis and helps firms combine their internal information with third-party data sources to create powerful data foundations. Intapp will integrate delphai's AI into solutions across its intelligent cloud platform, accelerating Intapp's AI roadmap. Additionally, Intapp will welcome the delphai team, including founder and CEO Robin Tech. The team comprises AI specialists with deep domain knowledge and experience at organizations including SAP, Google, Amazon, Salesforce, and MIT. These team members, from across product management, research and development, engineering, data, and support, will be at the center of Intapp's data strategy. The integration of Intapp and delphai's technologies in the coming months will offer clients access to advanced AI features and insights across Intapp's solutions. This will empower professionals worldwide to apply a wide range of native AI capabilities and leverage data more effectively so they can focus on what matters most: creating value.

08:32 EST Kineta to present new preclinical data on KVA12123 - Kineta announced that it will present new preclinical data on KVA12123, the Company's anti-VISTA antibody, in acute myeloid leukemia, AML, at the American Association for Cancer Research, AACR, Blood Cancer Discovery Symposium, to be held on March 4-6 in Boston, Massachusetts. Thierry Guillaudeux, Ph.D., Chief Scientific Officer of Kineta, will be presenting the poster.

08:31 EST H&E Equipment to slow 2024 gross fleet expenditures to $450M-$500M - Addressing 2024 strategic growth initiatives, Mr. Barber said, "We plan to slow our 2024 gross fleet expenditures to a range of $450 M to $500M. We believe our record fleet expenditures in 2023 and young fleet age advantageously position the Company to address the ongoing growth in construction markets and these factors should support steady improvement in physical utilization. Regarding our branch network, new branch growth will remain a fundamental component of our strategic plans in 2024 with 12 to 15 new locations expected in our branch expansion program. In addition, branch growth could be enhanced through attractive acquisition opportunities that offer access to vibrant construction markets in the U.S., as demonstrated by our latest acquisition which closed in early 2024, adding one location each in Phoenix and Denver." Mr. Barber noted the outlook for the equipment rental industry remains encouraging, supporting the point by saying, "Commentary from our customers regarding pending construction opportunities in 2024 remains optimistic and supports a business climate characterized by stable to modestly higher non-residential and industrial activity. Construction starts are projected to grow on a year-over-year basis with the growth reinforced by mega projects and increased spending on infrastructure programs. Also, we remain confident that expanding rental penetration will be a meaningful catalyst for increased industry growth."

08:26 EST AstraZeneca announces completion of acquisition of Gracell - AstraZeneca (AZN) announced the successful completion of the acquisition of Gracell Biotechnologies (GRCL), a global clinical-stage biopharmaceutical company developing innovative cell therapies for the treatment of cancer and autoimmune diseases, furthering AstraZeneca's cell therapy ambition. Under the terms of the definitive agreement, AstraZeneca has acquired all of Gracell's fully diluted share capital through a merger for a price of $2.00 per ordinary share in cash at closing plus a non-tradable contingent value right of $0.30 per ordinary share in cash payable upon achievement of a specified regulatory milestone.

08:23 EST Ree Automotive, Knapheide debut full vehicle solution - REE Automotive announced that its first demo P7-C fully by-wire chassis cab has arrived in the U.S. and has completed its upfitting at Knapheide in Quincy, Illinois. Knapheide, North America's most popular manufacturer of work truck bodies and truck beds, upfitted the P7-C with its KUV body, known to create optimized organization for the technician by dividing the storage space into manageable compartments that are externally accessible from either side of the body. "With REE's first of its kind fully by-wire vehicle technology and Knapheide's proven excellence with work truck bodies, we believe that REE and Knapheide will be able to provide the right body and equipment solutions for vocational fleets across North America," said Tali Miller, Chief Business Officer of REE Automotive. "Once upfitted, vocational fleets will be able to experience and drive REE vehicles on their routes and use it in their everyday activities. This is where we believe REE vehicles will really shine."

08:21 EST La Rosa Holdings acquires seventh real estate brokerage franchisee - La Rosa Holdings announced that it has acquired a 100% interest in the Company's franchisee - La Rosa Realty Winter Garden located in Winter Garden, Florida. Winter Garden generated revenue of $1.4 million and generated positive cash flow from operations. The franchisee provides residential and commercial real estate brokerage services. It also provides coaching and support services to agents on a fee basis.

08:18 EST Dare Bioscience to present additional data from Phase 2b RESPOND study - Dare Bioscience announced that additional data from the exploratory Phase 2b RESPOND clinical study of Sildenafil Cream, 3.6% in women with female sexual arousal disorder will be presented at the upcoming International Society for the Study of Women's Sexual Health Annual Meeting. These data include efficacy results across multiple endpoints in the proposed Phase 3 study population. "The data from the Phase 2b RESPOND study demonstrate that Sildenafil Cream treatment reduced sexual distress across multiple measures in a clinically meaningful way," said Dr. Andrew Goldstein, Medical Advisor for Dare Bioscience and former President of ISSWSH. "The results highlight specific endpoints with the strongest responses including arousal sensation, desire, orgasm, as well as stress, guilt, and embarrassment about the sexual dysfunction. Most importantly, based on these responses, we've identified the study population that will likely demonstrate the most significant benefit from Sildenafil Cream treatment, which consists of healthy premenopausal women with female sexual arousal disorder, including those who suffered from a lack of sexual desire due to their decreased arousal." Dr. Goldstein will also present data on sexual experiences from the study, which showed that Sildenafil Cream users had more sexual experiences and more solo sexual experiences than placebo users. Notably, Sildenafil Cream enhanced solo, unpartnered sexual experiences, which represented approximately 1 in 5 sexual events in the Phase 2b RESPOND study. Sildenafil, a phosphodiesterase-5 inhibitor, is the active ingredient in a tablet for oral administration currently marketed under the brand name Viagra for the treatment of erectile dysfunction in men. Sildenafil Cream is an investigational, proprietary topical cream formulation specifically designed to be used on-demand at the time of sexual activity to increase blood flow to the genital tissue in women. If development is successful, Sildenafil Cream has the potential to be the first product approved by the U.S. Food and Drug Administration to treat FSAD. Dare Bioscience previously announced a positive end-of-Phase 2 meeting with the FDA supporting advancement of Sildenafil Cream for the treatment of FSAD. The FDA recently confirmed that it aims to complete its review of the Phase 2b RESPOND study data and provide comments within the second quarter of 2024 on the proposed primary and secondary patient reported outcome endpoints for the planned Phase 3 pivotal trials of Sildenafil Cream to support potential product registration and labeling.

08:16 EST Comscore unveils update to Comscore Campaign Ratings - Comscore unveiled a significant update to its Comscore Campaign Ratings. This enhancement now extends deduplicated audience measurement to the local market level, which can be applied to all programmatic environments and platforms. CCR will, for the first time, integrate national and local linear TV, digital, streaming, and social channels. With the introduction of Comscore Campaign Ratings Local, Comscore has effectively bridged the last gap in cross-platform ad measurement, offering advertisers the tools needed for true reach and frequency optimization across the top 100 US local markets, with full coverage of all other local markets to follow. This expansion paves the way for complete local market coverage, revolutionizing how advertisers can harness data for precise, in-flight campaign adjustments across all media types.

08:15 EST Tilray selects MicroStar Logistics as long-term keg supply chain partner - Tilray Brands will consolidate and simplify its keg supply chain by converting to MicroStar's complete outsourced keg management solution. This move will support Tilray's strategy to grow efficiently, sustainably, and with the highest quality across its expanding national footprint. The following Tilray craft beer and beverage brands will soon be available in MicroStar-branded kegs: Alpine Beer Company, Blue Point Brewing Company, Breckenridge Brewery, Green Flash Brewing Company, Montauk Brewing Company, Redhook Brewery, Shock Top, SweetWater Brewing Company, 10 Barrel Brewing Co., Widmer Brothers Brewing, as well as Square Mile Cider.

08:13 EST Motus GI Holdings announces exercise of warrants for $2.7M gross proceeds - Motus GI Holdings has entered into a definitive agreement for the immediate exercise of an outstanding Series B common stock purchase warrant held by an institutional investor to purchase an aggregate of 2,933,334 shares of the Company's common stock for gross proceeds to the Company of approximately $2.7 million. As part of this transaction, the investor agreed to exercise the existing Series B common stock purchase warrant at a revised exercise price of $0.925 per share. The shares of common stock issuable upon exercise of the warrant were registered pursuant to an effective registration statement on Form S-1. In consideration for the immediate exercise of the existing warrant for cash, the Company has agreed to issue to the investor two new unregistered warrants, each to purchase 2,200,000 and 2,200,001 shares of common stock at an exercise price of $0.74 per share, respectively. The new warrants will be exercisable immediately upon issuance. Such warrants are identical, except that the first 2,200,000 warrants have a term of five years from the date of issuance and the second 2,200,001 warrants have a term of eighteen months from the date of issuance. A.G.P./Alliance Global Partners is acting as the exclusive financial advisor in connection with the offering. The transaction is expected to close no later than February 26, 2024, subject to satisfaction of customary closing conditions. The Company intends to use the net proceeds from the exercise for working capital and general corporate purposes.

08:13 EST Syra Health wins healthcare workforce contract from Douglas County, Nebraska - Syra Health has been awarded a healthcare workforce contract to provide temporary nursing staffing services in support of Douglas County, Nebraska, which includes the state's largest city, Omaha. Revenue generated from this contract is dependent on the number of positions Syra Health will staff and the duration of the positions. This contract marks the sixteenth state that Syra Health now has active healthcare workforce contracts in.

08:12 EST Arch Resources updates executive succession plan - Arch Resources announced that, as part of its long-term succession process, Richard Navarre will become Chair of Arch's Board of Directors at the conclusion of the company's annual stockholders' meeting on May 7, succeeding John Eaves, who will retire at that time as the company's executive chair and as a member of the board. James Chapman has also announced plans to retire from the Arch board at Arch's 2024 annual meeting. John Drexler has been promoted to the role of president, effective immediately, and nominated for election to the board of directors at the 2024 annual meeting. In addition to his role at Arch, Richard Navarre currently serves on the boards of Civeo Corporation and Natural Resource Partners. He is the past chairman and chief executive officer of Covia Corporation and earlier in his career served as president and chief commercial officer and as chief financial officer of Peabody Energy Corporation. John Drexler joined Arch in 1998 and has served as the company's senior vice president and COO since 2020. Prior to his current role, he served as Arch's senior vice president and CFO from 2008 through 2020 and as its vice president of finance and accounting from 2006 through 2008.

08:11 EST Verizon builds customizable 5G environment for Audi automotive test track - Verizon Business and Audi AG announced a partnership to build a private wireless network and tech-testing environment at Audi's automotive test track in Neustadt, Germany. The dynamic, multi-core wireless network is designed to duplicate network conditions in key markets around the world, with custom-built replicas of Verizon's U.S. public network, local European networks, and the roaming network of Audi's MVNO partner in Asia-Pacific.

08:10 EST Autonomix secures investigators, completes trialing for first human study - Autonomix Medical announced it has completed selection of Principal Investigators for its proof-of-concept human clinical study evaluating the use of transvascular RF ablation for the treatment of pancreatic cancer pain. Additionally, the Principal Investigators have successfully completed training for the PoC study. "We are building important momentum with the advancement of our PoC human clinical study. We worked diligently to identify and secure our Principal Investigators for the study and have completed the training for this first study ever to evaluate RF ablation in a transvascular approach. Our lead investigator performing the procedure is not only trained in interventional radiology, but he is also a cardiac surgeon. With these critical steps now completed, we remain on track to commence patient enrollment this quarter," commented Lori Bisson, Chief Executive Officer of Autonomix.

08:08 EST Spectral AI receives final stage of UKCA authorization for DeepView AI-Burn - Spectral AI announced that its predictive software DeepView AI-Burn has obtained the final stage of UK Conformity Assessed, UKCA, authorization, for aiding in burn wound diagnosis in the United Kingdom. "I am delighted to announce this achievement in our Company's evolution. The completion of this milestone will allow us to sell our DeepView System in the UK and we expect to swiftly deploy six devices in the UK for customer evaluation and to begin generating revenue in the second half of this year." said Wensheng Fan, the Company's Chief Executive Officer. "In addition, this regulatory authorization opens up the ability to expand partnerships with regions such as the Middle East that recognize the UKCA authorization." Revenue from commercialization in the UK in 2024 represents an addition to the $28 million revenue guidance previously communicated by the Company.

08:07 EST Bragg Gaming goes live at Golden Nugget in Michigan - Bragg Gaming announced that it has gone live with its newest games and Remote Game Server, or RGS, technology at Golden Nugget in Michigan. This milestone marks a significant step in Bragg's ongoing commitment to delivering innovative and engaging content to players across North America. Games now available to Golden Nugget's players in Michigan include popular titles such as "Cai Fu Emperor Ways" and "Egyptian Magic" from Bragg's Atomic Slot Lab, along with the thrilling "Devil's Lock" from Bluberi. All online casino games delivered on Bragg's new RGS technology come with the company's Fuze promotional tools as standard which offer player engagement features on games such as free rounds, tournaments and quests.

08:06 EST AbbVie, Tentarix announce multi-year collaboration - AbbVie and Tentarix Biotherapeutics announced a multi-year collaboration focused on the discovery and development of conditionally-active, multi-specific biologic candidates in oncology and immunology. The collaboration will integrate AbbVie's expertise in oncology and immunology with Tentarix's proprietary Tentacles platform. Under the terms of the agreements, Tentarix will receive upfront option payments, totaling $64M from AbbVie, for the two programs. AbbVie will receive an exclusive option to fully acquire the programs following candidate nomination, for an additional undisclosed payment for each program.

08:05 EST Analog Devices expands partnership with TSMC - Analog Devices (ADI) announced that the company has made a special arrangement with TSMC (TSM) to supply long-term wafer capacity through Japan Advanced Semiconductor Manufacturing, TSMC's majority-owned manufacturing subsidiary in Kumamoto Prefecture, Japan. Building on ADI's more than 30-year partnership with TSMC, this adds another option for ADI to secure additional capacity of fine-pitch technology nodes to serve critical platforms across its business, including wireless BMS and Gigabit Multimedia Serial Link applications. The joint efforts reinforce ADI's resilient hybrid manufacturing network, which helps to insulate external factors while supporting the means to increase output and scale rapidly to meet customer needs.

08:02 EST Golden Heaven authorizes $6M share repurchase program - Golden Heaven has authorized a share repurchase program authorizing the company to repurchase up to $6M of the company's outstanding Class A ordinary shares from time to time during a 24-month period. The company is not obligated to repurchase any specific number of Class A ordinary shares and the program may be modified, suspended, or discontinued at any time.

07:58 EST Silver Tiger Metals provides update on progress of pre-feasability study - Silver Tiger Metals provides an update on the Company's ongoing Pre-feasibility Study drilling program on the Stockwork gold deposit on its El Tigre Project in Sonora, Mexico. The Company continues to advance and de-risk the Stockwork Deposit. A 25,000 metre drilling program focused on Mineral Resource expansion and classification, metallurgical and geotechnical as it progresses from an exploration to a development project. The value-added PFS progresses on schedule for publication in H2-2024. Goals of the PFS drilling programs are to: de-risk the project with enhanced metallurgical and geotechnical review; increase confidence of the Mineral Resource with in-fill drilling in the near-surface 'Starter Pit'; and expand the known Mineral Resource through targeted drilling. During the PEA review, it was observed that three main areas of the Stockwork mineralization lacked adequate drilling and had potential for expansion: the footwall, the hanging wall and bottom 'keel'. Now, after releasing the first 15 drill holes of the program, the Company is pleased to announce conversion, expansion and de-risking of the potential 'Starter Pit'. Near-surface, Stockwork Zone, seen in below highlighted intercepts: Drill hole ET-23-479: 54.0 metres grading 0.85 g/t gold equivalent or 63.7 g/t silver equivalent or from 22.0 metres to 76.0 metres, consisting of 10.1 g/t silver and 0.71 g/t gold and 53.5 metres grading 110.0 g/t 1.47 g/t gold equivalent or silver equivalent from 96.5 metres to 150.0 metres consisting of 19.5 g/t silver and 1.21 g/t gold including 22.1 metres grading 2.06 g/t gold equivalent or 154.4 g/t silver equivalent from 97.9 metres to 120.0 metres consisting of 5.9 g/t silver and 1.98 g/t gold in the Stockwork Zone; Drill hole ET-23-486: 79.0 metres grading 0.86 g/t gold equivalent or 64.5 g/t silver equivalent from 104.0 metres to 183.0 metres, consisting of 31.3 g/t silver and 0.44 g/t gold including 26.0 metres grading 1.60 g/t gold equivalent or 119.7 g/t silver equivalent from 158.0 metres to 184.0 metres consisting of 85.2 g/t silver and 0.46 g/t gold in the Stockwork Zone; Drill hole ET-23-489: 89.5 metres grading 0.89 g/t gold equivalent or 67.1 g/t silver equivalent from 101.0 metres to 190.5 metres, consisting of 22.3 g/t silver and 0.60 g/t gold including 10.0 metres grading 1.50 g/t gold equivalent or 112.6 g/t silver equivalent from 110.0 metres to 120.0 metres consisting of 4.1 g/t silver and 1.45 g/t gold in the Stockwork Zone; and Drill hole ET-23-494: 78.1 metres grading 0.75 g/t gold equivalent or 56.5 g/t silver equivalent from 0.0 metres to 78.1 metres, consisting of 22.9 g/t silver and 0.45 g/t gold including 15.3 metres grading 0.93 g/t gold equivalent or 70.1 g/t silver equivalent from 3.0 metres to 18.3 metres consisting of 28.1 g/t silver and 0.56 g/t gold in the Stockwork Zone.

07:55 EST Medigus, ParaZero ramps up U.S. partnership with Vayu Aerospace - Medigus (MDGS) announced that on February 20, 2024 ParaZero Technologies (PRZO) announced that it has expanded its collaboration with Vayu Aerospace Corporation, a US-based drone original equipment manufacturer and subsidiary of Alpine 4 Holdings (ALPP). Boaz Shetzer, Chief Executive Officer of ParaZero commented, "We are glad to strengthen our partnership with Vayu, an innovator in autonomous drone technology. We have many successes from around the world in aiding our customers to achieve regulatory approvals for advanced operations using our SafeAir parachute systems. As we move forward integrating our SafeAir system from the design stage of Vayu's cutting-edge VTOLs, we are setting new standards in drone safety and functionality."

07:54 EST Rigel Pharmaceuticals acquires U.S. rights to Gavreto - Rigel Pharmaceuticals has entered into a definitive agreement to acquire the U.S. rights to Gavreto - pralsetinib - from Blueprint Medicines. Gavreto is a once daily, small molecule, oral, kinase inhibitor of wild-type RET - rearranged during transfection - and oncogenic RET fusions. Gavreto is approved by the FDA for the treatment of adult patients with metastatic RET fusion-positive non-small cell lung cancer - NSCLC - as detected by an FDA approved test. Gavreto is also approved for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory. Discussions with the FDA regarding confirmatory requirements are ongoing. Blueprint will receive a purchase price of $15.0M, $10.0M of which is payable upon first commercial sale by Rigel and an additional $5.0M of which is payable on the first anniversary of the closing date. Blueprint is also eligible to receive up to $97.5M in future commercial milestone payments and up to $5.0M in future regulatory milestone payments, in addition to tiered royalties ranging from 10% to 30%. Patents that have issued or are expected to issue covering GAVRETO will have statutory expiration dates between 2036 and 2041. Rigel expects to complete the transition of the asset and start recognizing product sales in Q3.

07:52 EST Ocular Therapeutix reports inducement grants under Nasdaq listing rule - Ocular Therapeutix has granted inducement equity awards to its newly appointed Executive Chairman, Pravin U. Dugel, MD and to its newly appointed Chief Strategy Officer, Sanjay Nayak, MBBS, PhD. The awards were approved by the Compensation Committee of Ocular and were made as inducements material to each individual's acceptance of employment with Ocular under Ocular's 2019 Inducement Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4). The inducement equity awards were granted to Dr. Dugel effective as of February 22, 2024 and consisted of a non-statutory stock option to purchase up to 1,282,469 shares of the Ocular's common stock at a per share exercise price equal to the closing price of Ocular's common stock on The Nasdaq Global Market on February 22, 2024 and a restricted stock unit award representing the right to receive 854,979 shares of Ocular's common stock. The stock option has a ten-year term and is scheduled to vest over four years, in equal monthly installments, beginning on the employment commencement date and subject to Dr. Dugel's continued service to Ocular through the applicable vesting dates. The restricted stock unit award is scheduled to vest over three years, in equal quarterly installments, beginning on the employment commencement date and subject to Dr. Dugel's continued service to Ocular through the applicable vesting dates. The inducement equity awards were granted to Dr. Nayak effective as of February 22, 2024 and consisted of a non-statutory stock option to purchase up to 244,550 shares of the Ocular's common stock at a per share exercise price equal to the closing price of Ocular's common stock on The Nasdaq Global Market on February 22, 2024 and a restricted stock unit award representing the right to receive 80,300 shares of Ocular's common stock. The stock option has a ten-year term and is scheduled to vest over four years, with 25% of the original number of shares vesting on the one-year anniversary of Dr. Nayak's employment commencement date and the remainder vesting in equal monthly installments over the three years thereafter, subject to Dr. Nayak's continued service to Ocular through the applicable vesting dates. The restricted stock unit award is scheduled to vest over three years, in equal quarterly installments, beginning on the employment commencement date and subject to Dr. Nayak's continued service to Ocular through the applicable vesting dates.

07:50 EST Allied Properties announces normal course issuer bid - Allied Properties Real Estate Investment Trust has received approval from the Toronto Stock Exchange for a normal course issuer bid which will enable it to purchase up to 12,629,698 of its 127,955,983 issued and outstanding units as at February 12, 2024, representing approximately 10% of its public float of 126,296,983 Units as at that date. Allied intends to commence the NCIB on February 26, 2024. The NCIB will expire on February 25, 2025, or such earlier date as Allied completes its purchases pursuant to the NCIB. All purchases under the NCIB will be made on the open market through the facilities of the TSX and/or alternate trading systems in Canada at market prices prevailing at the time of purchase. In accordance with TSX rules, any daily repurchases will be limited to a maximum of 98,743 Units, representing 25% of the average daily trading volume of the Units on the TSX for the six months ended January 31, 2024. Any Units that are repurchased will either be cancelled or delivered to participants under Allied's restricted unit plan or to employees pursuant to Allied's employee programs. Under its normal course issuer bid that commenced on February 24, 2023, Allied sought and received approval from the TSX to purchase up to 12,582,628 Units and repurchased 103,023 Units at a weighted average price of $17.44 per Unit. Such purchases were effected through the facilities of the TSX. The primary purpose of the NCIB is to purchase Units to fulfil Allied's commitments to employees under its restricted unit plan and other employee programs. Allied may also purchase Units for cancellation from time to time, depending on the market price of the Units and other factors.

07:48 EST Parsons prices $700M of convertible senior notes due 2029 - Parsons Corporation announced the pricing of its private offering of $700.0 million aggregate principal amount of its 2.625% convertible senior notes due 2029. In connection with the offering, Parsons entered into privately negotiated capped call transactions to offset potential dilution. Parsons also granted the initial purchasers in the offering an option to purchase, for settlement within a 13-day period beginning on, and including, the date on which the notes are first issued, up to an additional $100.0 million aggregate principal amount of notes. The sale of the notes to the initial purchasers is expected to settle on or about February 26, 2024, subject to customary closing conditions, and is expected to result in approximately $683.7 million in net proceeds to Parsons, after deducting the initial purchasers' discount and estimated offering expenses payable by Parsons but before deducting the cost of the capped call transactions. The notes will be senior unsecured obligations of Parsons. The notes will bear interest at a rate of 2.625% per annum, payable semiannually in arrears on March 1 and September 1 of each year, beginning on September 1, 2024. The notes will mature on March 1, 2029, unless earlier repurchased, redeemed or converted. The initial conversion rate for the notes is 10.6256 shares of Parsons' common stock per $1,000 principal amount of notes. Prior to October 1, 2028, the notes will be convertible at the option of the holders only upon the occurrence of specified events, and thereafter until the close of business on the second scheduled trading day immediately preceding the maturity date, the notes will be convertible at any time. Upon conversion, the notes will settle for cash and, if applicable, shares of Parsons' common stock. Parsons may redeem for cash all or any portion of the notes, at its option, on or after March 8, 2027 and before the 51st scheduled trading day immediately before the maturity date, but only if the last reported sale price per share of Parsons' common stock exceeds 130% of the conversion price for a specified period of time. The redemption price will be equal to the principal amount of the notes to be redeemed, plus accrued and unpaid interest, if any, to, but excluding, the redemption date. Parsons intends to use approximately $77.4 million of the net proceeds from the sale of the notes to fund the cost of entering into the capped call transactions described below and a portion of the net proceeds from the sale of the notes to repurchase a portion of its outstanding 0.25% Convertible Senior Notes due 2025 as follows: approximately $391.8 million of the net proceeds to repurchase approximately $228.1 million Existing Convertible Notes concurrently with the notes offering in privately negotiated transactions effected with or through one of the initial purchasers or its affiliate and approximately $56.5 million Existing Convertible Notes for an aggregate purchase price to be based in part on the daily volume-weighted average price per share of Parson's common stock over a measurement period following the pricing of the notes. Parsons intends to use the remainder of the net proceeds from the offering for general corporate purposes, including but not limited to, potential acquisitions and working capital. If the initial purchasers exercise their option to purchase additional notes, Parsons expects to use a portion of the additional net proceeds to fund the cost of entering into additional capped call transactions as described below. Any remaining proceeds will be used for general corporate purposes, including but not limited to, potential acquisitions and working capital.

07:46 EST InflaRx appoints Medina as Head of Investor Relations - InflaRx N.V announced the appointment of Jan Medina, CFA, as Vice President and Head of Investor Relations of InflaRx. Medina brings over 25 years of extensive experience across the life sciences sector and capital markets, including in the areas of investor relations, communications and equity research. Medina joins InflaRx from Olink Proteomics where he was Vice President, Investor Relations & Capital Markets.

07:44 EST AppTech's partner InstaCash on track to launch peer-to-peer payments platform - AppTech Payments announced that its strategic partner, InstaCash has gone live with its new www.instacash.cash website. InstaCash is now enrolling initial users for the upcoming launch of its innovative mobile-to-mobile payment system build on AppTech's patented FinZe platform. "Driven by AppTech's robust back-end technology and user support services, InstaCash aims to redefine industry standards for mobile payments with advanced security features and user-friendly functionality," said Luke D'Angelo, Chairman & CEO of AppTech. "As a licensor, partner, and equity stakeholder, AppTech supports InstaCash's mission of ushering in a new era of confidence in peer-to-peer mobile transactions."

07:41 EST Installed Building Products increases quarterly dividend 6% to 35c per share - IBP's board of directors declared the first quarter regular cash dividend of 35c per share, representing a 6% increase to the company's regular dividend. Edwards continued, "During 2023, we invested approximately $60 million in our acquisition strategy, while returning nearly $70 million to shareholders through dividends and share repurchases. We finished the year with a strong liquidity position and $387 million in cash on our balance sheet. As we continue to grow, we expect more capital will be returned to shareholders and the top priority within our capital allocation strategy remains pursuing accretive acquisitions. I am pleased to report that during the 2024 first quarter, our Board of Directors increased our regular quarterly cash dividend by 6% to $0.35 per share and declared an annual variable dividend of $1.60 per share, representing a $0.70 per share increase over last year's variable dividend."

07:37 EST Canopy Growth launches five new pre-roll products from 7ACRES and Hiway - Canopy Growth announced the introduction of five new pre-roll products across the company's adult-use cannabis portfolio from brands 7ACRES and Hiway.

07:33 EST Zimmer Biomet receives FDA clearance for ROSA Shoulder System - Zimmer Biomet announced U.S. FDA 510(k) clearance of the ROSA Shoulder System for robotic-assisted shoulder replacement surgery. ROSA Shoulder is the world's first robotic surgery system for shoulder replacement, and the fourth application for the company's comprehensive ROSA Robotics portfolio, which includes the ROSA Knee System for total knee arthroplasty and ROSA Hip System for total hip replacement. ROSA Shoulder will be commercially available in the U.S. in the second half of 2024, and will work with the mymobility Digital Care Management Platform to bolster the ZBEdge Dynamic Intelligence portfolio for patients undergoing shoulder replacement surgery.

07:31 EST Dominion to sell 50% noncontrolling inerest in Virginia offshore wind project - Dominion announced an agreement to sell a 50% noncontrolling interest in the Coastal Virginia Offshore Wind commercial project - CVOW - to Stonepeak through the formation of an offshore wind partnership. Under the terms of the agreement, Dominion Energy will retain full operational control of the construction and operations of CVOW. Stonepeak is an infrastructure investors with more than $61B in assets under management. Stonepeak will invest in a newly formed subsidiary of Dominion Energy Virginia. The subsidiary will be a public utility in Virginia entitled to recover its prudently incurred costs of constructing and operating the project under the existing Virginia offshore wind rider program. Cost-recovery will utilize the capital structure of and cost of capital at Dominion Energy Virginia. Dominion Energy will retain full operational control of the construction and operations of CVOW. Stonepeak will own a 50% noncontrolling equity interest and will have customary minority interest rights. The transaction is expected to close by the end of 2024 after all required approvals and consents have been received. At closing, Dominion Energy expects to receive proceeds of approximately $3B, representing 50% of the CVOW construction costs incurred through closing less $145M. If final construction costs of CVOW are $9.8B or less, excluding financing costs, Dominion Energy will receive $100M of the initial withholding. The transaction is expected to improve the company's estimated 2024 consolidated FFO-to-debt by approximately 1.0% and reduce the company's overall financing needs during construction. The 2.6-gigawatt CVOW, the largest offshore wind farm in the U.S., will consist of 176 turbines and three offshore substations in a nearly 113,000-acre lease area off the coast of Virginia Beach.

07:29 EST Osisko Development announces remaining drilling, results from Trixie test mine - Osisko Development announces the remaining drilling and underground chip sampling results from new development areas as part of its 2023 exploration program at its 100%-owned Trixie test mine, within the Company's wider Tintic Project, located in the historic East Tintic Mining District in central Utah, U.S.A.

07:26 EST White Gold discovers 1km long gold-in-soil anomaly northwest of VG Deposit - White Gold (WHGOF) announced that a soil sampling survey completed during the 2023 field season has identified a new 1 km long gold-in-soil anomaly on the QV property, located approximately 9 km northwest of the VG deposit which remains open for expansion. Soil sampling results range from trace up to a maximum of 496.7 ppb Au with associated anomalous tellurium. The new soil geochemical anomaly appears to be similar in character to the VG deposit and the Golden Saddle deposit which form part of the Company's flagship White Gold Project. The White Gold Project is located in west-central Yukon, Canada, and comprises 16 million tonnes averaging 2.23 g/t Au for 1,152,900 ounces of gold in the Indicated Resource category and 19 million tonnes averaging 1.54 g/t Au for 942,400 ounces of gold in the Inferred Resource category. These results form part of the Company's 2023 exploration program on its extensive and underexplored land package in the emerging White Gold District, Yukon, supported by strategic partners including Agnico Eagle Mines Limited (AEM) and Kinross Gold Corporation (KGC). Highlights: 2023 soil sampling survey on the QV property focused on two grids located east and west of Chris Creek and approximately 9 km northwest of the VG deposit, which hosts an open pittable Inferred resource of 287,100 oz gold at 1.53 g/t and remains open along strike and at depth. The soil sampling program consisted of approximately 200 samples collected at 50 m sample spacings on 100 m-spaced survey lines. Gold values range from less than 0.5 ppb Au to a maximum of 496.7 ppb Au, with 10 samples on the East Grid returning greater than 50 ppb Au in the range of 51.1 to 327 ppb Au. The gold anomaly is associated with anomalous tellurium and low arsenic in soils, which represents a surface geochemical signature similar to the VG and Golden Saddle deposits. The newly identified east-west trending soil anomaly on the East Grid measures approximately 1 km in length and is open along strike to the east and west beyond the limits of current soil sampling. Magnetic data indicates that the newly identified gold soil anomalies occur in a NNW-SSE trending mafic belt. Infill and extension soil sampling, GT-probe bedrock sampling, and ground magnetics and VLF-EM geophysical surveys are recommended to further advance this new target to drill-ready status in 2024.

07:25 EST Arqit Quantum, CableFree deliver first quantum-safe 5G products - Arqit Quantum and CableFree: Wireless Excellence announced the availability of integrated quantum-safe cellular technology products for Private 5G networks using Symmetric Key Agreement. David Williams, Arqit Founder, Chairman and CEO said: "In the USA, NIAP has mandated support of RFC 8784 meaning that symmetric key agreement will now at the heart of all CSfC classified networking, and we expect this to flow through to most commercial environments. The telecoms industry also needs to take urgent action now to secure sensitive data for the long-term. The integration of CableFree's 5G range with Arqit's unique Symmetric Key Agreement Platform will keep sensitive data and communications safe from current and future cyber threats including spoofing attacks and quantum computing."

07:23 EST Monopar Therapeutics announces preclinical data for its MNPR-101 program - Monopar Therapeutics announced promising preclinical imaging and therapeutic efficacy data for its MNPR-101 radiopharmaceutical program. This novel first-in-class radiopharma program targets cancers expressing the urokinase plasminogen activator receptor, which include a majority of all triple-negative breast, colorectal, and pancreatic cancers. Maximizing the dose delivered to the tumor relative to normal tissue is of paramount importance in radiopharmaceutical therapy. Monopar's in-house radiopharmaceutical development team was able to significantly increase tumor uptake of MNPR-101-Zr while minimizing uptake in healthy tissue, as shown in this preclinical positron emission tomography sequential imaging time-series. Preclinical data to date demonstrate compelling and durable anti-tumor benefits with MNPR-101 conjugated to therapeutic radioisotopes. The results in both show near complete elimination of the tumor after a single injection of the radiopharmaceutical agent. These studies demonstrate the potential of a MNPR-101 based radiopharmaceutical to provide a very meaningful clinical benefit to patients.

07:21 EST Autolus Therapeutics announces publication in Nature Communications - Autolus Therapeutics announces a publication in Nature Communications entitled: 'Structure-Guided Engineering of Immunotherapies Targeting TRBC1 and TRBC2 in T Cell Malignancies.' The targetable difference between TRBC1 and TRBC2 is very small - merely a 2 amino acid inversion. In this publication, the research team at Autolus first describe the structural basis for selective AUTO4 CAR recognition of TRBC1. This structure shows that some amino acid residues stabilize the interaction with the TCR generally, while others result in selectivity. By exploiting this structure, the research team used in silico design and phage display to flip selectivity of the AUTO4 binder from TRBC1 to TRBC2 to generate AUTO5, a TRBC2-specific CAR T cell therapeutic. "The development of a TRBC2-specific therapeutic by in silico design is a tour-de-force of structural biology and protein engineering from the research team at Autolus," said Dr Martin Pule Chief Scientific Officer and founder of Autolus. "T cell malignancies are a neglected clinical area and the development of AUTO5 along with AUTO4 could allow us to develop a broad therapeutic approach that exploits TRBC1/2 TCR biology."

07:19 EST Tilray launches new cannabis infused cold brew teas - Tilray Brands debuts two new ready-to-drink cold brew tea beverages by its premium cannabis wellness brand, Solei. Introducing Peach Cranberry and Wildberry Hibiscus, Solei's new cold brew tea offerings are non-carbonated and embrace a moderate elevation that's mildly sweet and comes in 355ml per can.

07:14 EST Pharvaris' deucrictibant shows positive results in HAE attacks - Pharvaris announced the upcoming presentation of two posters at the American Academy of Allergy, Asthma, & Immunology 2024 Annual Scientific Meeting in Washington D.C. February 23-26. The abstracts have been published in an online supplement to The Journal of Allergy and Clinical Immunology. The first poster reports on CHAPTER-1, a two-part, Phase 2 study evaluating the efficacy, safety, and tolerability of deucrictibant for long-term prophylaxis against angioedema attacks in hereditary angioedema, or HAE, type 1 and type 2. Analysis of the primary endpoint demonstrated that deucrictibant significantly reduced the monthly attack rate by 84.5% in participants dosed at 40 mg/day and 79.3% in participants dosed at 20 mg/day compared to placebo. Analyses of secondary endpoints demonstrated that treatment with deucrictibant reduced the occurrence of moderate and severe attacks and of attacks treated with on-demand medication compared to placebo, and a consistent reduction in monthly attack rate was observed with deucrictibant treatment regardless of baseline attack rate. Deucrictibant was well tolerated at both doses. A second poster will be presented during the poster session on February 23.

07:11 EST Rhythm Pharmaceuticals sees 2024 operating expenses $250M-$270M - For the year ending December 31, 2024, Rhythm anticipates approximately $250 million to $270 million in Non-GAAP Operating Expenses. Non-GAAP Operating Expenses are derived from: GAAP total operating expenses, inclusive of: SG&A expenses of $105 million to $110 million; and R&D expenses of $145 million to $160 million, inclusive of $10 million to $15 million of LB54640 development costs; but which excludes: Stock-based compensation, and $100 million in fixed consideration related to in-licensing of global rights to LB54640, which will be recognized in the first quarter of 2024.

07:08 EST Builders FirstSource increases stock repurchase plan to $1B - Builders FirstSource announced that its board authorized the repurchase of up to $1B of the Company's outstanding shares of common stock, inclusive of the approximately $200M remaining outstanding in the prior share repurchase plan authorized in April 2023.

07:08 EST Builders FirstSource sees FY24 capital expenditures $525M-$575M - Sees FY24 effective tax rate 23%-25%.

06:53 EST Chubb board to recommend increase in quarterly dividend to 91c per share - Chubb announced that its board will recommend to shareholders at the company's 2024 annual general meeting an increase in its quarterly dividend for the thirty-first consecutive year. The proposal calls for a $3.64 annual per share dividend, payable in four quarterly installments of 91c per share, compared to the current quarterly dividend amount of 86c per share. The board also declared a quarterly dividend equal to 86c per share, payable on April 5 to shareholders of record at the close of business on March 15. The dividend will be payable out of legal reserves and will be made in United States dollars by the company's transfer agent as described in the Chubb proxy statement. This will be the fourth installment as approved by the company's shareholders on May 17.

06:48 EST TechnipFMC reports total company backlog of $13.2B, up 41% y/y

06:32 EST Novavax to pay $80M annually to Gavi in settlement for COVID-19 vaccine APA - Novavax and Gavi, the Vaccine Alliance, announced they have reached a settlement related to the 2021 advance purchase agreement, or APA, for Novavax's prototype COVID-19 vaccine. This agreement brings the pending arbitration related to the APA to a close. With the goal of furthering a joint commitment to public health, Novavax and Gavi have agreed to terms that will prioritize Gavi's and Novavax's shared mission to save lives and protect people's health by increasing equitable and sustainable use of vaccines. Under the terms, Novavax has made an initial payment of $75M to Gavi and has agreed to make deferred payments of $80M annually through December 31, 2028, which are due in quarterly installments and total up to $400M. Novavax's annual cash obligation would be offset or reduced pursuant to an $80M annual vaccine credit, which may be used for qualifying sales of any of the company's vaccines funded by Gavi for supply to low-income and lower-middle income countries. Use of the annual vaccine credit for qualifying sales would reduce Novavax's annual cash obligation. In addition to the annual obligation, Novavax will provide an additional vaccine credit of up to $225M, should there be additional demand, which can be applied towards qualifying dose purchases of any of the Company's vaccines in such countries throughout the five-year term.

06:18 EST Clearway Energy raises quarterly dividend to 40.33c per share - On February 14, Clearway Energy's Board of Directors declared a quarterly dividend on Class A and Class C common stock of 40.33c per share payable on March 15 to stockholders of record as of March 1.

06:14 EST Radware expands relationship with NOS in Portugal - Radware announced that it expanded its relationship with NOS, one of the largest communications and entertainment groups in Portugal. The telecom leader is increasing its Radware security defenses to further safeguard traffic across its growing global cloud infrastructure and advance its reseller capabilities. NOS has 5.9M mobile phone customers, 1.6M television customers and over 5.3M households covered with FTTH. NOS chose Radware for its superior technology, technical expertise, and customer responsiveness.

06:10 EST Alight confirms receipt of director nominations from Starboard Value - Alight issued the following statement regarding Starboard Value's nomination of directors for election to the Alight Board of Directors at the company's 2024 Annual Meeting of Stockholders: "The Board and the company's management maintain an active dialogue with all types of investors and value their input and perspectives. While we have not had any engagement with Starboard to date, we welcome discussions on our strategy and creating shareholder value. The Board and its Nominating and Corporate Governance Committee will evaluate Starboard's nominees in the same manner as any other nominee and at the appropriate time will make a recommendation that best serves the interests of all of the company's stockholders. The company will announce details regarding the Annual Meeting in due course. Stockholders are not required to take any action at this time. Alight's Board maintains a commitment to identifying directors with the background and experience to enhance the Board's ability to drive stockholder value, as demonstrated by the addition of three new independent directors since going public in 2021. Alight's highly qualified Board has the skills, leadership qualifications and independence needed to guide Alight as it executes its strategic initiatives. Alight is successfully executing a strategy that is pivoting the company to a higher-growth, higher-margin operating model, which we expect to drive medium- and long-term value creation. We are starting 2024 with record revenue under contract, strong commercial momentum, and meaningful margin expansion potential. At the same time, we are conducting a strategic portfolio review to advance our platform and wellbeing strategy and identify opportunities to accelerate the achievement of our mid-term financial and strategic objectives."

06:08 EST Beam Global granted European patent for thermal management technology - Beam Global has been granted another new patent by the European Patent Office that covers the company's battery safety technology, with the patent title Thermal State of Charge Estimation of Phase Change Material in a Battery Pack with a PCM Thermal Management System. The European Patent Office granted European Patent No. EP 3 596 774 B1 for Beam Global's smart battery management system that monitors thermal storage capacity of Beam Global's proprietary phase change composite material and automatically adjusts the power output of the battery packs and cells as a function of the PCC thermal storage capacity to ensure a predetermined safe temperature limit.

06:06 EST Amwell names Cynthia Horner, M.D., as Chief Medical Officer - Amwell named Cynthia Horner, M.D., FAAFP, as its chief medical officer. Horner has also been named president of Amwell's clinical partner, Amwell Medical Group, a nationwide network of clinicians delivering virtual care 24 hours a day, every day, exclusively on the Amwell platform. Horner joined AMG in 2016 as a physician, before being named medical director and then AMG's head of general medicine and quality. Prior to Amwell, Horner practiced family medicine for 25 years. She also spent more than a decade as a board member for Helping Children Worldwide, where she counseled the non-profit on health-related programming for children and residents of Sierra Leone in West Africa.

06:01 EST NLRB rules employee's 'Black Lives Matter' action at Home Depot was protected - The NLRB on Wednesday issued a decision in Home Depot USA, Inc., holding that an employer violated the National Labor Relations Act when it discharged an employee for refusing to remove the hand-drawn letters "BLM" - the acronym for "Black Lives Matter" - from their work apron. Several other employees at the same store also displayed "BLM" markings on their work aprons at about the same time. Applying existing precedent, the Board reasoned that the employee's refusal to remove the BLM marking was "concerted" because it was a "logical outgrowth" of prior concerted employee protests about racial discrimination in their workplace and because it was an attempt to bring those group complaints to the attention of Home Depot managers. The employee's conduct was also "for mutual aid or protection" because the issue of racial discrimination involved employees' working conditions. "It is well-established that workers have the right to join together to improve their working conditions - including by protesting racial discrimination in the workplace," said Chairman Lauren McFerran. "It is equally clear that an employee who acts individually to support a group protest regarding a workplace issue remains protected under the law." Reference Link

05:49 EST Microsoft to use Intel to make home-grown chip - Microsoft (MSFT) plans to use Intel's (INTC) 18A technology to make a chip that Microsoft designed in-house, Intel said on Wednesday. Microsoft recently announced a computer processor and an AI accelerator. "We need a reliable supply of the most advanced, high-performance and high-quality semiconductors," Microsoft CEO Satya Nadella said in a statement. "That's why we are so excited to work with Intel." Reference Link

05:44 EST User reports indicate problems at T-Mobile, says Downdetector - Reference Link

05:43 EST User reports indicate problems at AT&T, says Downdetector - Reference Link

05:07 EST NaaS, Chancheng City Construction to establish RMB 1B construction joint venture - NaaS and Foshan Chancheng City Construction Group signed a strategic cooperation agreement at NaaS' headquarters in Anji, Zhejiang. The two parties will establish a joint venture with a planned investment of RMB 1B, focusing on new energy infrastructure investment management, in an effort to promote the construction and development of new energy infrastructure. The strategic cooperation agreement was signed by Sun Weilin, co-founder and CEO of NewLink, and Xu Jianxi, secretary of the party committee and chairman of Chancheng City Construction Group. Witnessing the signature ceremony were Chen Xinwen, director of Foshan Investment Promotion Bureau, Yu Xiang, VP of NaaS, Wu Yutao, Member of the party committee and deputy general Manager of Chancheng City Construction Group. Under the agreement, NaaS and Chancheng City Construction Group will establish a joint venture in Chancheng District, Foshan City, with a planned investment of RMB 1B. The joint venture will engage in various businesses including new energy infrastructure investment management, infrastructure operation and maintenance services, and charging safety testing.